Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiol Therapeutics (CRDL) Income from Continuing Operations (2020 - 2026)

Cardiol Therapeutics filings provide 2 years of Income from Continuing Operations readings, the most recent being 6269611.65 for Q4 2022.

  • On a quarterly basis, Income from Continuing Operations changed N/A to 6269611.65 in Q4 2022 year-over-year; TTM through Dec 2022 was 31375093.95, a N/A change, with the full-year FY2025 number at 24041007.65, up 15.78% from a year prior.
  • Income from Continuing Operations hit 6269611.65 in Q4 2022 for Cardiol Therapeutics, up from 10136512.64 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 5225536.31 in Q2 2021 to a low of 10136512.64 in Q3 2022.